Latest Eisai Stories
Clinical Study (003-011) to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD)
RnRMarketResearch.com adds “Arterial Thrombosis – Pipeline Review, H1 2015” report to its store.
GIA announces the release of a comprehensive global report on the CNS Therapeutics.
DALLAS, March 4, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Epilepsy - Pipeline Review, H1 2015" therapeutic market research report of 330 pages with latest updates,
DALLAS, March 3, 2015 /PRNewswire/ -- ReportsnReports.com offers Cancer Cachexia - Pipeline Review, H1 2015 research report that provides an overview of the Cancer Cachexia's
-- Conference Call and Webcast Scheduled for Today at 5:00 p.m. Eastern Time -- SAN DIEGO, March 2, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
A New Drug Approved for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer WOODCLIFF LAKE, N.J.,
Eisai Demonstrates Commitment to Patients with Rare Cancers WOODCLIFF LAKE, N.J., Feb. 25, 2015 /PRNewswire/ -- Eisai Inc.
WOODCLIFF LAKE, N.J., Feb. 19, 2015 /PRNewswire/ -- Eisai Inc.
DALLAS, February 13, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Dementia - Pipeline Review, H1 2015" to its store.
- Large; stout; burly.